Federica Pecci, Research Fellow of Thoracic Oncology at Dana-Farber Cancer Institute, shared on LinkedIn:
“Happy to share our manuscript entitled ‘Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report’ just published in Journal of Thoracic Oncology.
Our findings suggests that TMB may serve as a dual-purpose biomarker, identifying patients both more likely to benefit from ICIs and more likely to experience irAEs.
Huge thanks to Xinan Wang for co-leading the study, Biagio Ricciuti for his amazing mentorship, and to all the co-authors Alessandro Di Federico, Edoardo Garbo, Mihaela Aldea, Narjust Florez, Bill Lotter, Giulia Bruschi, Mark Awad, Pasi Jänne, Elad Sharon, Eleonora Gariazzo, Valentina Santo and many others.”
Title: Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report
Authors: Federica Pecci, Xinan Wang, Valentina Santo, Eleonora Gariazzo, Edoardo Garbo, Francesco Paoloni, Guilherme Rossato de Almeida, Mihaela Aldea, Alessandro Di Federico, Joao V. Alessi, Stephanie Canty, Giulia Bruschi, William Lotter, Mark M. Awad, Alexander Gusev, Narjust Florez, David C. Christiani, Scott J. Rodig, Mizuki Nishino, Pasi A. Jänne, Elad Sharon, Biagio Ricciuti
Other articles featuring Federica Pecci on OncoDaily.